Data updated: Mar 10, 2026
CAMCEVI KIT
LEUPROLIDE MESYLATE
Approved 2021-05-25
1
Indication
--
Phase 3 Trials
4
Years on Market
Details
- Status
- Prescription
- First Approved
- 2021-05-25
- Routes
- SUBCUTANEOUS
- Dosage Forms
- EMULSION
CAMCEVI KIT Approval History
Loading approval history...
What CAMCEVI KIT Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CAMCEVI KIT FDA Label Details
ProCAMCEVI KIT Patents & Exclusivity
Latest Patent: Dec 2038
Patents (5 active)
US11717555
Expires Jan 1, 2039
US12133878
Expires Dec 18, 2037
US10646572
Expires Jan 16, 2027
US9744207
Expires Jan 16, 2027
US9572857
Expires Jan 16, 2027
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.